Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanjiv K. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
- Beta
- 1.74
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 25.51
Financials
Revenue
$0.00-100.0%Net Income
$-81.75MEBITDA
$-81.47MFree Cash Flow
$-63.93MEPS (diluted)
$-0.37Shares Outstanding (diluted)
219.16M+6996.1%Operating Expenses
$90.25MCash & Debt
$848.64MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $15.36M | $-276.48M | $-1.61 |
| 2024 | $10.01M | $-337.71M | $-2.36 |
| 2023 | $25.55M | $-341.97M | $-2.79 |
| 2022 | $1.38M | $-290.51M | $-2.59 |
| 2021 | $3.03M | $-363.87M | $-3.82 |
| 2020 | $82.65M | $-52.41M | $-2.56 |
| 2019 | $0.00 | $-66.50M | $-15.53 |
| 2018 | $0.00 | $-48.78M | $-19.63 |
Valuation
RLAYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·20d ago·Neutral
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November:
View source ↗ - Newsdefenseworld.net·42d ago·Negative
Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in Stock Relay Therapeutics, Inc. (NASDAQ: RLAY - Get Free Report) CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $18.10, for a total value of $872,401.90. Following the completion of the sale, the chief executive officer owned 471,301 shares of
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Neutral
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
View source ↗ - 4chan /biz/biz·111d ago·Neutral
>>62553499 How otherwise do you think disabling Replace-By-Fee (RBF) works than? The race. Thousands of at-risk wallets need to be swept to fresh seeds over the coming days and weeks. For each of them there is exactly one dangerous window: the time between the sweep transaction hitting the mempool and it confirming in a block. During that window, an attacker holding the keys can broadcast a conflicting transaction paying a higher fee and redirect everything. A miner running full-RBF will happi
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.38 per share
Typical surprise +6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.37 vs $-0.40beat
- Thu, Aug 6$-0.41 vs $-0.39miss
- Tue, May 5$-0.41 vs $-0.35miss
- Thu, Feb 26$-0.32 vs $-0.38beat
- Thu, Nov 6$-0.43 vs $-0.39miss
- Thu, Aug 7$-0.41 vs $-0.49beat
Estimates and results for RLAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RLAY officers and directors.
- Bought
- —
- Sold
- $129.0m
0 trades
61 trades
- Rahmer Petersold
- Bergstrom Donald Asold
- Catinazzo Thomassold
- Patel Sanjivsold
- Catinazzo Thomassold
- Catinazzo Thomassold
- Bergstrom Donald Asold
- Catinazzo Thomassold
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
